GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Bausch Health Companies Inc (NYSE:BHC) » Definitions » Gross Margin %

BHC (Bausch Health) Gross Margin % : 70.08% (As of Jun. 2024)


View and export this data going back to 1994. Start your Free Trial

What is Bausch Health Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. Bausch Health's Gross Profit for the three months ended in Jun. 2024 was $1,684 Mil. Bausch Health's Revenue for the three months ended in Jun. 2024 was $2,403 Mil. Therefore, Bausch Health's Gross Margin % for the quarter that ended in Jun. 2024 was 70.08%.


The historical rank and industry rank for Bausch Health's Gross Margin % or its related term are showing as below:

BHC' s Gross Margin % Range Over the Past 10 Years
Min: 70.78   Med: 71.97   Max: 75.26
Current: 70.8


During the past 13 years, the highest Gross Margin % of Bausch Health was 75.26%. The lowest was 70.78%. And the median was 71.97%.

BHC's Gross Margin % is ranked better than
84.27% of 966 companies
in the Drug Manufacturers industry
Industry Median: 47.005 vs BHC: 70.80

Bausch Health had a gross margin of 70.08% for the quarter that ended in Jun. 2024 => Durable competitive advantage

The 5-Year average Growth Rate of Gross Margin for Bausch Health was -0.50% per year.


Bausch Health Gross Margin % Historical Data

The historical data trend for Bausch Health's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bausch Health Gross Margin % Chart

Bausch Health Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Gross Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 72.68 71.98 71.61 70.90 70.78

Bausch Health Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Gross Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 70.05 72.16 70.72 70.27 70.08

Competitive Comparison of Bausch Health's Gross Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, Bausch Health's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bausch Health's Gross Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Bausch Health's Gross Margin % distribution charts can be found below:

* The bar in red indicates where Bausch Health's Gross Margin % falls into.



Bausch Health Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue.

Bausch Health's Gross Margin for the fiscal year that ended in Dec. 2023 is calculated as

Gross Margin % (A: Dec. 2023 )=Gross Profit (A: Dec. 2023 ) / Revenue (A: Dec. 2023 )
=6198 / 8757
=(Revenue - Cost of Goods Sold) / Revenue
=(8757 - 2559) / 8757
=70.78 %

Bausch Health's Gross Margin for the quarter that ended in Jun. 2024 is calculated as


Gross Margin % (Q: Jun. 2024 )=Gross Profit (Q: Jun. 2024 ) / Revenue (Q: Jun. 2024 )
=1684 / 2403
=(Revenue - Cost of Goods Sold) / Revenue
=(2403 - 719) / 2403
=70.08 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Bausch Health  (NYSE:BHC) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Bausch Health had a gross margin of 70.08% for the quarter that ended in Jun. 2024 => Durable competitive advantage


Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.


Bausch Health Gross Margin % Related Terms

Thank you for viewing the detailed overview of Bausch Health's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Bausch Health Business Description

Traded in Other Exchanges
Address
2150 Saint Elzear Boulvard West, Laval, QC, CAN, H7L 4A8
Bausch Health Companies Inc is a global specialty pharmaceutical, consumer health, and medical device company with a focus on branded products for the gastroenterology, hepatology, neurology and dermatology markets. The company reports revenue in five segments: Salix; International; Solta Medical; Diversified Products and Bausch + Lomb. It generates maximum revenue from the Bausch + Lomb segment.
Executives
Seana Carson officer: EVP, General Counsel 400 SOMERSET CORPORATE BLVD, BRIDGEWATER NJ 08807
John S Barresi officer: SVP, Controller & CAO 727 FIFTH AVENUE, NEW YORK NY 10022
Richard Mulligan director C/O ICAHN CAPITAL LP, 767 FIFTH AVENUE, SUITE 4700, NEW YORK NY 10153
Tom George Vadaketh officer: EVP, Chief Financial Officer 1727 JOCKEYS WAY, YARDLEY PA 19067
Robert Spurr director, officer: U.S. President-Pharma Business C/O BAUSCH HEALTH COMPANIES INC., 400 SOMERSET CORPORATE BLVD., BRIDGEWATER NJ 08807
Joseph F Gordon officer: Pres&Co-Head Bausch&Lomb/Int'l C/O BLCO, 400 SOMERSET CORPORATE BLVD., BRIDGEWATER NJ 08807
Frederick Munsch officer: SVP, Controller and CAO C/O BLCO, 400 SOMERSET CORPORATE BLVD., BRIDGEWATER NJ 08807
Christina Ackermann officer: EVP AND GENERAL COUNSEL C/O BLCO, 400 SOMERSET CORPORATE BLVD., BRIDGEWATER NJ 08807
Sam Eldessouky officer: EVP & Chief Financial Officer C/O BLCO, 400 SOMERSET CORPORATE BLVD., BRIDGEWATER NJ 08807
Steven D Miller director 16690 COLLINS AVENUE, PH, SUNNY ISLE BEACH FL 33160
Von Eschenbach Andrew C. director C/O BLCO, 400 SOMERSET CORPORATE BLVD., BRIDGEWATER NJ 08807
De Schutter Richard U director C/O BLCO, 400 SOMERSET CORPORATE BLVD., BRIDGEWATER NJ 08807
Brett Icahn director C/O ICAHN ENTERPRISES L.P., 16690 COLLINS AVE., PH, SUNNY ISLES FL 33160
William D. Humphries officer: EVP, COMPANY GROUP CHAIRMAN C/O STRATA SKIN SCIENCES, INC., 5 WALNUT GROVE DRIVE SUITE 140, HORSHAM PA 19044
Valueact Capital Master Fund, L.p. director, other: See remarks ONE LETTERMAN DRIVE, BUILDING D, 4TH FLOOR, SAN FRANCISCO CA 94129